Recombinant adeno-associated virus (AAV) vectors have emerged as a new vector for gene therapy, and they have been widely used in clinical trials to treat a variety of diseases.
Construction of thymosin beta-4 recombinant adeno-associated virus
A phase 2 study to evaluate the safety and immunogenicity of a recombinant adeno-associated virus
Gene Therapy Progress and Prospects: Recombinant adeno-associated virus
is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus
(AAV) gene therapy.
Alameda, CA; 510-748-7150), announced the completion of a strategic licensing agreement granting biotech company Stratagene worldwide exclusive rights to sell kits for making the company's proprietary recombinant adeno-associated virus
vectors for research purposes.
The allowed patent includes composition of matter claims which cover the essential component of any adeno-associated virus gene delivery system, specifically any recombinant adeno-associated virus
vector products, free of contaminating wild-type adeno-associated virus, regardless of the method of production.